5.78
+0.44(+8.24%)
Currency In USD
Address
245 Main Street
Boston, MA 02142
United States of America
Phone
781-797-0979
Website
Sector
Healthcare
Industry
Biotechnology
Employees
79
First IPO Date
May 06, 2022
| Name | Title | Pay | Year Born |
| James G. McArthur | President, Chief Executive Officer, Treasurer, Secretary & Director | 850,668 | 1962 |
| Michael Gait | Founder & Scientific Advisory Board Member | 282,162 | N/A |
| Paul D. Streck | Executive VP and Head of Research & Development | 332,733 | 1964 |
| Noel Donnelly | Chief Financial Officer | 633,705 | 1970 |
| Afsaneh Mohebbi | Senior Vice President of Portfolio and Program Management | 0 | N/A |
| Hayley Parker | Senior Vice President of Global Regulatory Affairs | 0 | N/A |
| Kasra Kasraian | Chief Technology Officer | 0 | N/A |
| Joseph D. Vittiglio | Chief Business & Legal Officer | 0 | 1972 |
| Emiko Bryant | Chief of Staff, HR & Operations | 0 | N/A |
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.